These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19366369)

  • 1. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level.
    Huang J; Tefferi A
    Eur J Haematol; 2009 Aug; 83(2):154-5. PubMed ID: 19366369
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.
    Crisà E; Cilloni D; Elli EM; Martinelli V; Palumbo GA; Pugliese N; Beggiato E; Frairia C; Cerrano M; Lanzarone G; Marchetti M; Mezzabotta M; Boccadoro M; Ferrero D
    Br J Haematol; 2018 Sep; 182(5):701-704. PubMed ID: 29984826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not.
    Tefferi A; Mesa RA; Pardanani A; Hussein K; Schwager S; Hanson CA; Steensma DP
    Am J Hematol; 2009 May; 84(5):265-7. PubMed ID: 19396855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis.
    Hernández-Boluda JC; Correa JG; García-Delgado R; Martínez-López J; Alvarez-Larrán A; Fox ML; García-Gutiérrez V; Pérez-Encinas M; Ferrer-Marín F; Mata-Vázquez MI; Raya JM; Estrada N; García S; Kerguelen A; Durán MA; Albors M; Cervantes F
    Eur J Haematol; 2017 Apr; 98(4):407-414. PubMed ID: 28009442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does anything work for anaemia in myelofibrosis?
    Birgegård G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):175-85. PubMed ID: 25189728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for leukemic transformation in patients with primary myelofibrosis.
    Huang J; Li CY; Mesa RA; Wu W; Hanson CA; Pardanani A; Tefferi A
    Cancer; 2008 Jun; 112(12):2726-32. PubMed ID: 18404742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating low-risk myelodysplastic syndromes in the community setting.
    Cripe LD
    Clin Adv Hematol Oncol; 2008 Jun; 6(6):418-20. PubMed ID: 18567986
    [No Abstract]   [Full Text] [Related]  

  • 8. Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence.
    Passamonti F; Rumi E; Elena C; Arcaini L; Merli M; Pascutto C; Cazzola M; Lazzarino M
    Br J Haematol; 2010 Sep; 150(6):719-21. PubMed ID: 20560961
    [No Abstract]   [Full Text] [Related]  

  • 9. Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Komrokji R; Steensma D; Balleari E; Götze KS; Kotsianidis I; Guerci-Bresler A; Stamatoullas A; Sanz GF; Germing U; Fenaux P
    Leuk Res; 2020 Dec; 99():106472. PubMed ID: 33212326
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-dose thalidomide in myelofibrosis.
    Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
    Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
    [No Abstract]   [Full Text] [Related]  

  • 11. Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents.
    Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP
    Leukemia; 2003 Aug; 17(8):1669-70. PubMed ID: 12886259
    [No Abstract]   [Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
    Pirker R
    Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.
    Benetatos L; Chaidos A; Alymara V; Vassou A; Bourantas KL
    Eur J Haematol; 2005 Mar; 74(3):273-4. PubMed ID: 15693801
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older.
    Ibrahim HN; Ishani A; Guo H; Gilbertson DT
    Nephrol Dial Transplant; 2009 Oct; 24(10):3138-43. PubMed ID: 19451656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Primary myelofibrosis (osteomyelosclerosis). Current views on the pathogenesis, clinical course, diagnosis and therapy].
    Demidova AV
    Ter Arkh; 1974; 46(8):19-29. PubMed ID: 4422055
    [No Abstract]   [Full Text] [Related]  

  • 16. Our patient pulled a fast one on Medicare--and on us.
    Lamon JM
    Med Econ; 2000 Aug; 77(15):170-2. PubMed ID: 11010281
    [No Abstract]   [Full Text] [Related]  

  • 17. [Physiopathological and cytogenetic investigations of a case of myelofibrosis treated successfully with androgens].
    Pileri A; Masera P; Pegoraro L; Gavosto F
    Haematologica; 1966; 51(1):57-72. PubMed ID: 4956677
    [No Abstract]   [Full Text] [Related]  

  • 18. Update on anemia management in nephrology, including current guidelines on the use of erythropoiesis-stimulating agents and implications of the introduction of "biosimilars".
    Locatelli F; Becker H
    Oncologist; 2009; 14 Suppl 1():16-21. PubMed ID: 19762513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.
    Lee J
    Ann Hematol; 2009 Jul; 88(7):699-700. PubMed ID: 19030859
    [No Abstract]   [Full Text] [Related]  

  • 20. 1-25 (OH)2 D3 in idiopathic myelofibrosis: a preliminary report.
    Petrini M; Cecconi N; Ambrogi F; Grassi B
    Haematologica; 1987; 72(6):567-9. PubMed ID: 3126118
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.